DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for ET Mutual Funds Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE FRI, NOV 08, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Happy Friday! Buried in the election news this week was new data from drugmakers vying to enter the booming weight loss drug market.  Pharmaceutical giant AstraZeneca and biotech company Viking Therapeutics were among the companies that presented encouraging data on their obesity pills and other treatments at the ObesityWeek conference in San Antonio, Texas, in recent days.  Wall Street is betting that the new wave of growth in the obesity space will be driven by pills that could offer more convenience and potentially fewer side effects, which could keep patients on the drugs for longer. Analysts expect the weight loss drug market to be worth more than $100 billion by the end of the decade as more treatments emerge and help meet the demand that existing injections from Novo Nordisk and Eli Lilly are st